اسأل أو ابحث عن أي شيء...
Hot Research Today
Papers from every journal, all in one place. أنشئ موجزات مخصصة.
2w ago
Expert CommentaryTop JournalCirculation Highlight
Level 2: RCT
Pulsed Field Ablation Versus Sham to Treat Atrial Fibrillation: The PFA-SHAM Randomized Clinical Trial
Pulsed field ablation cuts 6-month atrial tachyarrhythmia recurrence by ~92% versus sham.
Implication
PFA markedly outperforms sham for AF recurrence and QoL; confirms ablation benefit beyond placebo in symptomatic patients.
Circulation
Charles University
1w ago
Expert CommentaryTop JournalCirculation Highlight
Level 1: Clinical Guideline
Role of Physical Activity in Obesity Treatment and Cardiometabolic Health: A Scientific Statement From the American Heart Association
Implication
Prescribe physical activity for cardiometabolic gains irrespective of weight loss; extends evidence for multimodal obesity management.
Circulation
4w ago
Trending on XExpert CommentaryTop JournalCirculation Highlight
Level 2: RCT
Angiotensin Receptor Neprilysin Inhibitor in Heart Failure with Preserved Ejection Fraction and Secondary Mitral Regurgitation: the PRAISE-MR Randomized Trial
Sacubitril/valsartan improves exercise mPAP/CO slope by ~0.93 mmHg/L/min versus SOC in HFpEF with AFMR.
Implication
Supports sacubitril/valsartan over SOC in HF with adverse exercise hemodynamics; extends prior ARNI trials to this invasive endpoint.
“The PRAISE-MR trial is the first prospectively randomized trial to demonstrate that sacubitril/valsartan significantly improves exercise hemodynamics, functional capacity, and quality of life in patients with HFpEF and AFMR. These findings underscore that the phenotypic heterogeneity of HFpEF nec...”
— ACC Journal ScanView source
Circulation
Vrije Universiteit Brussel
2w ago
Expert CommentaryTop JournalESC Press Release Highlight
Level 1: Clinical Guideline
Women's heart centres: a clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the Heart Failure Association (HFA), and the Association for Acute CardioVascular Care (ACVC) of the ESC
Implication
Supports women's heart centre implementation to reduce sex-based care gaps; extends consensus on specialized pathways and training.
European Heart Journal
Harvard University
2w ago
Trending on XTop JournalACC Journal Scan Highlight
Level 1: Meta-Analysis
Adverse Effects and Treatment Discontinuation of Blood Pressure–Lowering Drugs and Combinations
CCBs increase adverse event discontinuations ~43% versus placebo while ARB monotherapy reduces them.
Implication
CCBs raise and ARBs lower adverse-event discontinuations versus placebo; extends class-specific tolerability data to inform initial antihypertensive selection.
“Results from the study by Wang, et al., can help inform clinicians' selection of antihypertensive therapies for patients initiating medications for hypertension, particularly when comorbidities, such as the presence of diabetes with microvascular disease, do not warrant a specific therapy.”
— ACC Journal ScanView source
JAMA
University of Oxford
1w agoOpen Access
Expert CommentaryTop JournalCirculation Highlight
Level 3: Cohort Study
Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials
Each 10% intervention-induced loss of visceral adipose tissue was associated with a 28% lower risk of incident type 2 diabetes (HR 0.72; 95% CI 0.54-0.94) during 5- and 10-year follow-up.
Implication
Visceral fat loss may inform diabetes prevention targets; hypothesis-generating and requires randomized confirmation.
“Repeated participation in a lifestyle program for weight loss, even after a perceived 'failure,' may lead to significant health benefits over the years, especially in reducing dangerous abdominal fat.”
— Iris ShaiView source
Circulation
Harvard University
1w ago
Top Journal
Level 1: Meta-Analysis
Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages
Finerenone reduced cardiovascular and kidney events across CKM stages and increased CKM syndrome regression (11.4% vs 7.4%; aOR 1.66; 95% CI 1.30-2.13; P<.001) compared with placebo.
Implication
Supports finerenone across CKM stages in T2D-CKD; extends prior RCTs to include syndrome regression.
“Importantly, participants who experience new-onset AFib/AFL were at a substantially higher subsequent risk of adverse cardiovascular and kidney outcomes than were those who remained free of AFib/AFL during follow-up. These findings highlight the role of finerenone in reducing the risk of new-onset AFib/AFL, mitigating downstream complications, and ultimately improving outcomes in patients across the CKM spectrum.”
— Dr. Maria A. PabonView source
JAMA Cardiology
University of Michigan
1w ago
Top Journal
Level 2: RCT
Precardioversion Heart Rhythm Monitoring Using Smartphone Photoplethysmography
Precardioversion monitoring using smartphone photoplethysmography significantly reduced same-day cancellations of scheduled cardioversions compared to standard care (4.8% vs 23.2%; P<.001).
Implication
Reduces same-day cancellations and resource waste in AF cardioversion; extends smartphone photoplethysmography evidence to preprocedural monitoring.
JAMA Cardiology
Karolinska Institutet
1w ago
Expert CommentaryTop JournalACC Journal Scan Highlight
Level 2: RCT
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
Low-dose rivaroxaban did not reduce the composite of cardiovascular events compared with placebo in patients with advanced CKD (HR 1.09; 95% CI 0.87-1.36; P=0.46).
Implication
Does not support low-dose rivaroxaban for cardiovascular prevention in advanced CKD; confirms lack of efficacy with increased major bleeding.
“TRACK sets the direction for the questions that must be asked next, particularly regarding which patients are most likely to benefit (e.g., those with established cardiovascular disease) and whether alternative oral anticoagulation strategies may prove more effective or safer in selected CKD popu...”
— ACC Journal ScanView source
JAMA
University College London
4w ago
Expert CommentaryTop JournalACC Journal Scan Highlight
Level 3: Cohort Study
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy
CMR LGE% predicts ~86% higher adverse event risk in HCM, alongside NT-proBNP.
Implication
LV scar burden by LGE may refine HCM risk stratification; this observational link extends prior markers but leaves open prospective validation before guiding therapy.
“This is an important next step to do a better job of identifying HCM patients at high risk," he said. "This adds to presently used risk markers derived from the patient's and their family's prior history.”
— ACC Journal ScanView source
JAMA
University of Michigan
